EMEA-001811-PIP02-15-M04
Table of contents
Key facts
| Active substance |
ligelizumab
|
| Therapeutic area |
Dermatology
|
| Decision number |
P/0308/2021
|
| PIP number |
EMEA-001811-PIP02-15-M04
|
| Pharmaceutical form(s) |
|
| Condition(s) / indication(s) |
Treatment of chronic spontaneous urticaria
|
| Route(s) of administration |
Subcutaneous use
|
| Contact for public enquiries |
Novartis EuroPharm Ltd.
Tel.: +41 613241111 |
| Decision type |
PM: decision on the application for modification of an agreed PIP
|